NDA 021153 · Astrazeneca
Nexium
Esomeprazole Magnesium · Oral
Priority reviewLast checked: Nov 20, 2026Latest source record: Jul 18, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2001
Feb 20, 2001
Approved uses
4
Original approval plus efficacy supplements
Registered trials
522
102 Phase 3, 23 recruiting
FAERS reports
184,794
125,906 serious, 14,871 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 19, 2025.
NEXIUM is a proton pump inhibitor (PPI). NEXIUM delayed-release capsules and NEXIUM for delayed-release oral suspension are indicated for the: • Short-term treatment in the healing of erosive esophagitis (EE) in adults and pediatric patients 12 years to 17 years of age. ( 1.1 ) • Maintenance of healing of EE in adults. ( 1.2 ) • Short-term treatment of heartburn and other symptoms associated GERD in adults and pediatric patients 12 years to 17 years of age. ( 1.3 ) • Risk reduction of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers. ( 1.4 ) • Helicobacter pylori eradication in adult patients to reduce the risk of duodenal ulcer recurrence in combination with amoxicillin and clarithromycin. ( 1.5 ) • Long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome in adults. ( 1.6 ) NEXIUM for delayed-release oral suspension is indicated for the: • Short-term treatment in the healing of EE in pediatric patients 1 year to 11 years of age and of EE due to acid-mediated GERD in pediatric patients 1 month to less than 1 year of age. ( 1.1 ) • Short-term treatment of heartburn and other symptoms associated with GERD in pediatric patients 1 year to 11 years of age. ( 1.3 ) 1.1 Healing of Erosive Esophagitis (EE) Adults NEXIUM delayed-release capsules and NEXIUM for delayed-release oral suspension are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed EE in adults. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4- to 8- week course of NEXIUM may be considered. Pediatric Patients 12 Years...
Mechanism: Esomeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell. Esomeprazole is protonated and converted in the acidic compartment of the parietal cell forming the active inhibitor, the achiral sulphenamide. Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, esomeprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production....
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 11, 2006 Supplement 23 · Efficacy LetterLabel
- Apr 28, 2006 Supplement 22 · Efficacy · priority review LabelLetter
- Nov 24, 2004 Supplement 19 · Efficacy LetterLabel
- Feb 20, 2001 Original approval · Type 2 - New Active Ingredient · priority review ReviewOther Important Information from FDAPediatric Written Request
2 products under this application
- NEXIUM · ESOMEPRAZOLE MAGNESIUM EQ 20MG BASE · CAPSULE, DELAYED REL PELLETS, ORAL · Prescription · TE AB
- NEXIUM · ESOMEPRAZOLE MAGNESIUM EQ 40MG BASE · CAPSULE, DELAYED REL PELLETS, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Esomeprazole" as an intervention, any sponsor and status, largest first.
- Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer MortalityPivotal-lookingRecruiting
International Agency for Research on CancerAcademic, hospital or other
NCT02047994 · 30,000 participants (planned) · Start Mar 2013 · Primary completion Dec 2033
Drug: Triple therapy · For: Helicobacter Pylori Infections; Atrophic Gastritis; Gastric Cancer
Sites: Riga, Latvia
- Community-based Helicobacter Pylori EradicationStatus unknown
National Taiwan University HospitalAcademic, hospital or other
NCT00155389 · 5,000 participants (planned) · Start Jan 2004 · Primary completion Dec 2015
Drug: Helicobacter pylori eradication · For: Helicobacter Pylori Infection
Sites: Taipei, Taiwan · 2 sites in all
- Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled TrialPivotal-lookingNot yet recruiting
Fudan UniversityAcademic, hospital or other
NCT06943794 · 4,824 participants (planned) · Start Mar 30, 2026 · Primary completion May 1, 2030
Drug: recommendations for Hp eradication treatment · For: Gastric (Stomach) Cancer
Sites: Tongling, China
- Nexium (Esomeprazole) in Symptom Adapted Therapy in GERD PatientsPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00444275 · 3,029 participants · Start Mar 2007 · Primary completion Oct 2008
Drug: esomeprazole (Nexium®); Xolaam® · For: GERD
Sites: Rouen, France
- A Multi-center Study for Individual Treatment of Helicobacter Pylori InfectionPivotal-lookingStatus unknown
First Affiliated Hospital of Zhejiang UniversityAcademic, hospital or other
NCT02689583 · 3,000 participants (planned) · Start Mar 2016 · Primary completion Mar 2017
Drug: Antibiotic selection based on the antibiotic susceptibility testing · For: Gastritis; Gastric Ulcer
- A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's MetaplasiaPivotal-lookingCompleted
University of OxfordAcademic, hospital or other
NCT00357682 · 2,557 participants · Start Mar 10, 2005 · Primary completion May 31, 2017
Drug: Esomeprazole; Esomeprazole and 1 more · For: Esophageal Cancer; Precancerous Condition
- Study of Esomeprazole 20 mg or 40 mg vs Placebo Effectiveness on the Occurrence of Peptic Ulcers in Subjects on Low Dose Acetylsalicylic Acid (LDA)Pivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00441727 · 2,426 participants · Start Feb 2007 · Primary completion Aug 2008
Drug: Esomeprazole 40 mg; Esomeprazole 20 mg and 1 more · For: Gastric Ulcer; Duodenal Ulcer
Sites: Birmingham, Alabama; Tucson, Arizona; Anaheim, California · 189 sites in all
- Examine National Characteristics & Outcome Measures of GERD Patients Using the PPI Acid Suppression Symptom (PASS) Test for ResponsePivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00392002 · 2,000 participants · Start Oct 2005
Drug: Esomeprazole · For: Gastroesophageal Reflux
Sites: Mississauga, Canada; Toronto, Canada
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- chronic kidney disease33,708
- acute kidney injury17,592
- renal failure14,997
- drug ineffective11,529
- gastrooesophageal reflux disease11,038
- drug dose omission10,970
- nausea10,406
- end stage renal disease9,816
- renal injury8,915
- pain8,591
- diarrhoea7,953
- malaise7,946
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 2,032 |
| 2005 | 2,746 |
| 2006 | 3,529 |
| 2007 | 4,467 |
| 2008 | 5,251 |
| 2009 | 6,620 |
| 2010 | 8,243 |
| 2011 | 13,211 |
| 2012 | 22,370 |
| 2013 | 7,117 |
| 2014 | 7,345 |
| 2015 | 10,485 |
| 2016 | 10,084 |
| 2017 | 8,080 |
| 2018 | 21,309 |
| 2019 | 21,821 |
| 2020 | 7,600 |
| 2021 | 6,011 |
| 2022 | 4,385 |
| 2023 | 3,285 |
| 2024 | 3,034 |
| 2025 | 3,532 |
| 2026 | 2,234 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Nexium (Esomeprazole Magnesium)
2024 spending
$59.7M
Beneficiaries
20,438
97,946 claims
Per beneficiary
$2,922
$8.85 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $106,028,083 |
| 2021 | $94,196,779 |
| 2022 | $84,185,655 |
| 2023 | $74,209,509 |
| 2024 | $59,728,475 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative effectiveness and tolerability of esomeprazole and omeprazole in gastro-esophageal reflux disease: A systematic review and meta-analysis.
Qi Q, Wang R, Liu L, et al. · Int J Clin Pharmacol Ther 2015 · Comparative Study, Meta-Analysis
- Proton pump inhibitors are not associated with an increased risk of Clostridioides difficile infection: a systematic review and meta-analysis of randomized controlled trials.
Floria DE, Obeidat M, Váncsa S, et al. · Gut Microbes 2025 · Systematic Review, Meta-Analysis
- Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole.
Yang E, Kim S, Kim B, et al. · Br J Clin Pharmacol 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis.
Lee KJ, Son BK, Kim GH, et al. · Aliment Pharmacol Ther 2019 · Clinical Trial, Phase III, Comparative Study
- Randomized controlled trial to evaluate the efficacy and safety of fexuprazan compared with esomeprazole in erosive esophagitis.
Lee KN, Lee OY, Chun HJ, et al. · World J Gastroenterol 2022 · Randomized Controlled Trial
- Proton pump inhibitors alter gut microbiota by promoting oral microbiota translocation: a prospective interventional study.
Xiao X, Zhang X, Wang J, et al. · Gut 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: AstraZeneca
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.